Salix Pharmaceuticals
(https://salix.com) 📸 Data Snapshot: June 19, 2026Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
The homepage exhibits a high fluff-to-substance ratio, leading with power-word-heavy headings like [H1] For Us, There Is No Finish Line and [H2] MOVEMENT without specific metrics or nouns. While the History sub-page provides significant density with drug names and licensing dates, this data is nearly seven years stale as of June 2026, ending in 2019. The About Us page further dilutes density with vague phrases like ‘Your Share of Possible’ and ‘The Highest Standards’ that lack supporting data. Consequently, the site relies on a single page of historical records to carry the weight of its current pharmaceutical authority.
Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.
📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE · THIN (https://salix.com) Home | Salix Pharmaceuticals
SeeProductList [H3] Proven Treatments Effective solutions for a wide range of patients Discover The Future [H3] Promising Pipeline Rigorous research and development to advance innovative products View The Good [H3] Committed Care Building a community based on integrity and mutual respect
SUB-PAGE · THIN (https://salix.com/about-us/contact-us/) Contact Us | Salix Pharmaceuticals
[H1] Visit, Ask, Connect [H4] Corporate Headquarters Salix Pharmaceuticals is located in Bridgewater, New Jersey, about an hour south of New York City and an hour north of Philadelphia. 400 Somerset Corporate Blvd.Bridgewater, NJ 08807 USAPhone: 1-800-321-4576 [H4] Customer Support Phone: 800-321-4576 [H4] U.S. Medical Information Submit Medical Inquiry [H4] For Media Inquiries Salix PharmaceuticalsEmail: salixcommunications@salix.com
SUB-PAGE · THIN (https://salix.com/about-us/) About Us | Salix Pharmaceuticals
See Compliance Commitment [H3] The Highest Standards We realize that operating with transparency develops and fosters trust Contact Us [H3] Visit, Ask, Connect Have a medical, investor, or media-related question? JOIN THE JOIN THE A long history of
SUB-PAGE (https://salix.com/about-us/history/) History | Salix Pharmaceuticals
[H1] Every Journey Starts With a Step We started ours in 1989 when our founders, Randy W. Hamilton and Lorin K. Johnson, PhD, realized the need for more effective gastrointestinal solutions. Since then, Salix hasn’t stopped moving forward. [H4] 1989 - Salix Pharmaceuticals is founded in Sunnyvale, California [H4] 1990 - COLAZAL® (balsalazide disodium) is licensed [H4] 1996 - XIFAXAN® (rifaximin) is licensed [H4] 2000 - Operations move to Raleigh, North Carolina- COLAZAL® (balsalazide disodium) receives FDA approval [H4] 2004 - XIFAXAN® (rifaximin) 200 mg receives FDA approval [H4] 2006 - MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) receives FDA approval [H4] 2008 - APRISO® (mesalamine granules) receives FDA approval- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval [H4] 2009 - OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) receives FDA approval Prescribing Information, including BOXED WARNING. [H4] 2010 - XIFAXAN® (rifaximin) 550 mg receives FDA approval [H4] 2013 - UCERIS® (budesonide) extended-release tablets receives FDA approval- GIAZO® (balsalazide disodium) 1.1g tablets receive FDA approval [H4] 2014 - Salix acquires Santarus- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval for an additional indication [H4] 2015 - UCERIS® (budesonide) rectal foam receives FDA approval- XIFAXAN® (rifaximin) 550 mg receives FDA approval for additional indication- Valeant acquires Salix- Operations begin moving to Bridgewater, New Jersey, our current location [H4] 2016 - Salix launches RELISTOR® (methylnaltrexone bromide) tablets [H4] 2017 - Salix scales up sales force by nearly 40 percent [H4] 2018 - Valeant changes name to Bausch Health- Salix launches PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) [H4] 2019 - Salix celebrates three decades of GI solutions- Bausch Health completes acquisition of certain assets of Synergy Pharmaceuticals, including Trulance (plecanatide) Prescribing Information, including BOXED WARNING. - Salix Pharmaceuticals announces inaugural scholarship program to commemorate its 30th anniversary
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
This page presents a snapshot of public data from Salix Pharmaceuticals, captured on June 19, 2026, to show how machine logic reads Information Density signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Salix Pharmaceuticals: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://salix.com to view the most current version of its content and see directly what this company is about and what it offers.